Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors ...

A pioneering blood test detected more than twice as many high-risk prostate cancer cases as current methods, paving the way for more effective screening.

A new blood test may make it easier to detect the most dangerous forms of prostate cancer early. In a study from Karolinska ...

The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...

AI is increasingly integrated within prostate cancer diagnosis pathway. A systematic search of PubMed, Embase, Cochrane, Scopus and Web of Science from January 2017 to October 2024 was performed for ...

State-funded clinical study will validate the OTraces’ proteomic blood test ability to reduce unnecessary prostate biopsies in men with elevated PSA ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...

A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...

Androgen deprivation therapy (ADT) has long been the cornerstone of treatment for advanced prostate cancer. Since ...